Multiple endocrine neoplasia, type 1 (MEN 1), sometimes called Wermer's syndrome, is a rare disorder that causes tumors in the endocrine glands and parts of the small intestine and stomach. In MEN 1, the endocrine glands — usually the parathyroids, pancreas and pituitary — grow tumors and release excessive amounts of hormones that can lead to disease. However, the tumors are usually noncancerous (benign).

The excess hormones can cause a wide variety of signs and symptoms, such as tiredness, bone pain, fractures and kidney stones, as well as stomach or intestinal ulcers. Although MEN 1 can't be cured, regular testing can detect problems, and doctors can provide treatment as needed.

MEN 1 is an inherited disorder, meaning people who have the gene mutation can pass it on to their children. Each child has a 50 percent chance of inheriting the disorder.

Multiple endocrine neoplasia, type 1 (MEN 1) care at Mayo Clinic

Aug. 25, 2017
  1. Jameson JL, et al., eds. Multiple endocrine neoplasia type 1. In: Endocrinology: Adult and Pediatric. 7th ed. Philadelphia, Pa.: Saunders Elsevier; 2016. https://www.clinicalkey.com. Accessed July 12, 2017.
  2. Melmed S, et al. Multiple endocrine neoplasia. In: Williams Textbook of Endocrinology. 13th ed. Philadelphia, Pa.: Elsevier; 2016. https://www.clinicalkey.com. Accessed July 12, 2017.
  3. Multiple endocrine neoplasia type 1. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/endocrine-diseases/multiple-endocrine-neoplasia-type-1. Accessed July 12, 2017.
  4. Warner K. Allscripts EPSi. Mayo Clinic, Rochester, Minn. March 3, 2017.
  5. Multiple endocrine neoplasia, type 1 (MEN 1). Merck Manual Professional Version. https://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/multiple-endocrine-neoplasia-men-syndromes/multiple-endocrine-neoplasia,-type-1-men-1. Accessed July 12, 2017.
  6. Arnold A. Multiple endocrine neoplasia type 1: Treatment. https://www.uptodate.com/contents/search. Accessed July 12, 2017.
  7. Ospina NS, et al. Safety and efficacy of percutaneous parathyroid ethanol ablation in patients with recurrent primary hyperparathyroidism and multiple endocrine neoplasia type 1. The Journal of Clinical Endocrinology and Metabolism. 2015;100:E87.
  8. Nippoldt TB (expert opinion). Mayo Clinic, Rochester, Minn. July 17, 2017.